News in brief: Mortality benefit of antifibrotics in IPF; ATS slams inhaler move by Big Tobacco; Mandatory vax needed for all hospital staff

Mortality benefit of antifibrotics in IPF Antifibrotic treatment appears to reduce the risk of all-cause mortality and acute exacerbation in patients with IPF. A systematic review and meta-analysis of the evidence, comprising 12,956 patients across 26 studies, found antifibrotic treatment was associated with decreased risk of all-cause mortality with a pooled RR 0.55. The meta-analysis ...

Already a member?

Login to keep reading.

© 2021 the limbic